ArticleEuropean journal of cancer (Oxford, England : 1990)2018

Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?

Satish Shanbhag et al.PubMed ↗Publisher ↗

No numbers read from the abstract.